Aura Minerals Inc. has been upgraded to a Strong Buy rating despite a 35% drop in its stock price since April. The downgrade in price is attributed to temporary challenges such as geopolitical issues, a shift in copper preference, and weak first-quarter results causing operational and cost pressures. However, the company's fundamentals and long-term outlook remain solid, supported by valuation models showing significant upside potential—45.6% from a 5-year discounted cash flow analysis and 28.7% from price-to-net asset value. Key positive catalysts include possible inclusion in the GDX ETF, increased dividends, a $200 million share buyback, and favorable gold market conditions in the second half of the year, though risks related to operations and gold prices remain.
Harmony Biosciences announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Dayno will remain as a non-executive advisor through 2027 to support the com...
Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patien...
The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million house...
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus n...
Iridex Corporation announced a two-year clinical study demonstrating that MicroPulse transscleral laser therapy significantly reduces intraocular pressure (IOP) and medication use in patients with early to advanced glaucoma. The study, involving 84 e...
